Table 6. Results of LiPA in detecting rifampin resistance in clinical specimens in which MTBC was correctly identified and cultured, stratified by history of antituberculous treatment*.
| Treatment history | No. positive/no. tested (%) |
||||
|---|---|---|---|---|---|
| Concordance | Sensitivity | Specificity | PPV | NPV | |
| Current or within 3 mo | 46/48 (95.8) | 8/10 (80.0) | 38/38 (100) | 8/8 (100) | 38/40 (95.0) |
| >3 mo ago | 41/42 (97.6) | 7/7 (100) | 34/35 (97.1) | 7/8 (87.5) | 34/34 (100) |
| None stated | 689/691 (99.7) | 23/23 (100) | 666/668 (99.7) | 23/25 (92.0) | 666/666 (100) |
*LiPA, line probe assay; MTBC, Mycobacterium tuberculosis complex; AFB, acid-fast bacilli; PPV, positive predictive value; NPV, negative predictive value.